Evidence map›Paper›PMID 39856133›Full record

ArticleScientific reports2025

KLRB1 expression in nasopharyngeal mucosa as a prognostic biomarker in COVID-19 patients.

Marilina García-Aranda, María Ángeles Onieva, Desirée Martín-García, Raúl Quirós, Inmaculada López, María Padilla-Ruiz, Teresa Téllez, Beatriz Martínez-Gálvez, María Luisa Hortas, Alberto García-Galindo and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Marilina García-ArandaResearch and Innovation Unit, Costa del Sol University Hospital, Autovía A-7, km 187, Marbella, 29603, Spain. marilina.garcia@ibima.eu.
María Ángeles OnievaPreventive Medicine Unit, Costa del Sol University Hospital, Autovía A-7, km 186, Marbella, 29603, Spain.
Desirée Martín-GarcíaResearch and Innovation Unit, Costa del Sol University Hospital, Autovía A-7, km 187, Marbella, 29603, Spain.
Raúl QuirósInternal Medicine Unit, Costa del Sol University Hospital, Autovía A-7 km 187, Marbella, 29603, Spain.
Inmaculada LópezMicrobiology Unit, General Clinical Analysis Service, Costa del Sol University Hospital, Autovía A-7, km 187, Marbella, 29603, Spain.
María Padilla-RuizResearch and Innovation Unit, Costa del Sol University Hospital, Autovía A-7, km 187, Marbella, 29603, Spain.
Teresa TéllezResearch and Innovation Unit, Costa del Sol University Hospital, Autovía A-7, km 187, Marbella, 29603, Spain.
Beatriz Martínez-GálvezMalaga Biomedical Research Institute (IBIMA-Plataforma BIONAND), Calle Severo Ochoa, 35. 29590, Malaga, Spain.
María Luisa HortasClinical Analysis Service, Costa del Sol University Hospital, Autovía A-7 km 187, Marbella, 29603, Spain.
Alberto García-GalindoInstitute of Data Science and Artificial Intelligence (DATAI), University of Navarra, Ismael Sánchez Bella Building, Campus Universitario, Pamplona, 31009, Spain.
José González-GomarizInstitute of Data Science and Artificial Intelligence (DATAI), University of Navarra, Ismael Sánchez Bella Building, Campus Universitario, Pamplona, 31009, Spain.
Rubén ArmañanzasInstitute of Data Science and Artificial Intelligence (DATAI), University of Navarra, Ismael Sánchez Bella Building, Campus Universitario, Pamplona, 31009, Spain.
Francisco Rivas-RuizResearch and Innovation Unit, Costa del Sol University Hospital, Autovía A-7, km 187, Marbella, 29603, Spain.
Alfonso SerranoImmunology & Clinical Analysis Service, Virgen de la Victoria University Hospital, Campus de Teatinos, Malaga, 29010, Spain.
Isabel Barragán-Mallofret *Medical Oncology Unit Virgen de la Victoria, Malaga Biomedical Research Institute (IBIMA-Plataforma BIONAND), Calle Severo Ochoa, 35. 29590, Malaga, Spain.
Maximino Redondo *Research and Innovation Unit, Costa del Sol University Hospital, Autovía A-7, km 187, Marbella, 29603, Spain. mredondo@uma.es.

Funding

European Social Fund-Operational Program of Andalusia 2014-2020 - Consejería de Salud y Familias de la Junta de Andalucía RH-0055-2020Fundación Fuerte & Isabel Luque Bardón FF-ILBGobierno de Navarra ANDIA 2021 - PORTRAIT 0011-3947-2021-00023 AND 0011-2750-2022-0000Sistema Andaluz de Salud - Nicolás Monardes RC-0009-2021University of Malaga-Consejería de Transformación Económica, Industria, Conocimiento y Universidades-Junta de Andalucia CV20-76497
6 · The paper itself

Abstract

The resurgence of COVID-19 and the rise in severe outcomes emphasize the need for reliable prognostic markers to guide patient care and optimize ICU and hospital resources. This study investigates the potential of nasopharyngeal swabs to identify biomarkers that predict ICU admission or death in hospitalized COVID-19 patients. We analyzed nasopharyngeal exudates from 95 hospitalized patients in 2020 using high-plex RNA quantification on the NanoString

Indexed as

COVID-19Nasal MucosaNasopharynxAdultAgedBiomarkersFemaleHumansIntensive Care UnitsMaleMiddle AgedPrognosisRisk FactorsSARS-CoV-2BiomarkersBiomarkerCOVID-19KLRB1Nasopharyngeal mucosaPrognosis

Identifiers

PMID39856133
PMCPMC11761047

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.